Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in ARASENS : Overall and Japanese Subgroup Results
International Journal of Urology · 2026
DOI: 10.1111/iju.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Kenji Tanabe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Decision Support Techniques, Androgen Antagonists, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the benefit–risk of adding darolutamide to androgen‐deprivation therapy (ADT) plus docetaxel in ARASENS, in the overall population and the Japanese subgroup, using Bayesian multi‐criteria decision analysis (MCDA).
Methods
Bayesian MCDA was conducted using published aggregate data from ARASENS. A three‐criterion model was evaluated based on overall survival (OS), grade 3/4 adverse events, and treatment discontinuation. Additional models included five criteria in the overall cohort (adding time to castration‐resistant prostate cancer [TTCRPC] and undetectable prostate‐specific antigen) and four criteria in the Japanese subgroup (adding TTCRPC). Prespecified weights summing to one were applied, and 100 000 posterior simulations estimated the probability that the triplet provided greater utility (P[ΔU > 0]). Weight‐scenario sensitivity analyses were conducted.
Results
In the overall cohort, the darolutamide triplet achieved net clinical benefit across weight scenarios except the toxicity‐only, driven by OS/TTCRPC benefits with minimal safety penalties. In the Japanese subgroup, the three‐criterion model yielded P(ΔU > 0) of 0.601, reflecting wide OS uncertainty and a higher discontinuation rate. When TTCRPC was incorporated, P(ΔU > 0) increased to 0.975. However, this increase was driven primarily by the TTCRPC component, while the OS contribution remained imprecise due to the small subgroup size.
Conclusions
Bayesian MCDA integrated multiple clinical endpoints to examine how differing value preferences influence decision‐making. Scenario‐based analysis demonstrated a consistent benefit of adding darolutamide to ADT and docetaxel, while revealing that varying efficacy–safety weightings affected confidence in overall utility among Japanese.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Urology, Zigong Fourth People's Hospital, Sichuan, China.
- Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
- Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Kenji Tanabe, Soichiro Yoshida, Hiroshi Fukushima, Hajime Tanaka
Zitieren
APA
Tanabe, K., Yoshida, S., Chen, W., Yajima, S., Sato, H., Hirakawa, A., Fukushima, H., Yasuda, Y., Tanaka, H., Masuda, H., & Fujii, Y. (2026). Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in ARASENS : Overall and Japanese Subgroup Results. International Journal of Urology. https://doi.org/10.1111/iju.70384
Vancouver
Tanabe K, Yoshida S, Chen W, Yajima S, Sato H, Hirakawa A, et al. Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in ARASENS : Overall and Japanese Subgroup Results. International Journal of Urology. 2026. doi:10.1111/iju.70384
BibTeX
@article{Tanabe2026,
author = {Tanabe, Kenji and Yoshida, Soichiro and Chen, Wei and Yajima, Shugo and Sato, Hiroyuki and Hirakawa, Akihiro and Fukushima, Hiroshi and Yasuda, Yosuke and Tanaka, Hajime and Masuda, Hitoshi and Fujii, Yasuhisa},
title = {Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in ARASENS : Overall and Japanese Subgroup Results},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70384}
}
EUVIMED